Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models.
Africa South of the Sahara
/ epidemiology
Anti-HIV Agents
/ supply & distribution
Antiretroviral Therapy, Highly Active
Betacoronavirus
/ pathogenicity
COVID-19
Condoms
/ supply & distribution
Coronavirus Infections
/ epidemiology
Female
Global Health
/ trends
HIV Infections
/ epidemiology
HIV-1
/ drug effects
Humans
Incidence
Infant, Newborn
Infectious Disease Transmission, Vertical
/ prevention & control
Male
Models, Statistical
Pandemics
Pneumonia, Viral
/ epidemiology
SARS-CoV-2
Sexual Behavior
/ psychology
Survival Analysis
Journal
The lancet. HIV
ISSN: 2352-3018
Titre abrégé: Lancet HIV
Pays: Netherlands
ID NLM: 101645355
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
06
05
2020
revised:
25
06
2020
accepted:
29
06
2020
pubmed:
11
8
2020
medline:
17
9
2020
entrez:
11
8
2020
Statut:
ppublish
Résumé
The COVID-19 pandemic could lead to disruptions to provision of HIV services for people living with HIV and those at risk of acquiring HIV in sub-Saharan Africa, where UNAIDS estimated that more than two-thirds of the approximately 38 million people living with HIV resided in 2018. We aimed to predict the potential effects of such disruptions on HIV-related deaths and new infections in sub-Saharan Africa. In this modelling study, we used five well described models of HIV epidemics (Goals, Optima HIV, HIV Synthesis, an Imperial College London model, and Epidemiological MODeling software [EMOD]) to estimate the effect of various potential disruptions to HIV prevention, testing, and treatment services on HIV-related deaths and new infections in sub-Saharan Africa lasting 6 months over 1 year from April 1, 2020. We considered scenarios in which disruptions affected 20%, 50%, and 100% of the population. A 6-month interruption of supply of antiretroviral therapy (ART) drugs across 50% of the population of people living with HIV who are on treatment would be expected to lead to a 1·63 times (median across models; range 1·39-1·87) increase in HIV-related deaths over a 1-year period compared with no disruption. In sub-Saharan Africa, this increase amounts to a median excess of HIV deaths, across all model estimates, of 296 000 (range 229 023-420 000) if such a high level of disruption occurred. Interruption of ART would increase mother-to-child transmission of HIV by approximately 1·6 times. Although an interruption in the supply of ART drugs would have the largest impact of any potential disruptions, effects of poorer clinical care due to overstretched health facilities, interruptions of supply of other drugs such as co-trimoxazole, and suspension of HIV testing would all have a substantial effect on population-level mortality (up to a 1·06 times increase in HIV-related deaths over a 1-year period due to disruptions affecting 50% of the population compared with no disruption). Interruption to condom supplies and peer education would make populations more susceptible to increases in HIV incidence, although physical distancing measures could lead to reductions in risky sexual behaviour (up to 1·19 times increase in new HIV infections over a 1-year period if 50% of people are affected). During the COVID-19 pandemic, the primary priority for governments, donors, suppliers, and communities should focus on maintaining uninterrupted supply of ART drugs for people with HIV to avoid additional HIV-related deaths. The provision of other HIV prevention measures is also important to prevent any increase in HIV incidence. Bill & Melinda Gates Foundation.
Sections du résumé
BACKGROUND
The COVID-19 pandemic could lead to disruptions to provision of HIV services for people living with HIV and those at risk of acquiring HIV in sub-Saharan Africa, where UNAIDS estimated that more than two-thirds of the approximately 38 million people living with HIV resided in 2018. We aimed to predict the potential effects of such disruptions on HIV-related deaths and new infections in sub-Saharan Africa.
METHODS
In this modelling study, we used five well described models of HIV epidemics (Goals, Optima HIV, HIV Synthesis, an Imperial College London model, and Epidemiological MODeling software [EMOD]) to estimate the effect of various potential disruptions to HIV prevention, testing, and treatment services on HIV-related deaths and new infections in sub-Saharan Africa lasting 6 months over 1 year from April 1, 2020. We considered scenarios in which disruptions affected 20%, 50%, and 100% of the population.
FINDINGS
A 6-month interruption of supply of antiretroviral therapy (ART) drugs across 50% of the population of people living with HIV who are on treatment would be expected to lead to a 1·63 times (median across models; range 1·39-1·87) increase in HIV-related deaths over a 1-year period compared with no disruption. In sub-Saharan Africa, this increase amounts to a median excess of HIV deaths, across all model estimates, of 296 000 (range 229 023-420 000) if such a high level of disruption occurred. Interruption of ART would increase mother-to-child transmission of HIV by approximately 1·6 times. Although an interruption in the supply of ART drugs would have the largest impact of any potential disruptions, effects of poorer clinical care due to overstretched health facilities, interruptions of supply of other drugs such as co-trimoxazole, and suspension of HIV testing would all have a substantial effect on population-level mortality (up to a 1·06 times increase in HIV-related deaths over a 1-year period due to disruptions affecting 50% of the population compared with no disruption). Interruption to condom supplies and peer education would make populations more susceptible to increases in HIV incidence, although physical distancing measures could lead to reductions in risky sexual behaviour (up to 1·19 times increase in new HIV infections over a 1-year period if 50% of people are affected).
INTERPRETATION
During the COVID-19 pandemic, the primary priority for governments, donors, suppliers, and communities should focus on maintaining uninterrupted supply of ART drugs for people with HIV to avoid additional HIV-related deaths. The provision of other HIV prevention measures is also important to prevent any increase in HIV incidence.
FUNDING
Bill & Melinda Gates Foundation.
Identifiants
pubmed: 32771089
pii: S2352-3018(20)30211-3
doi: 10.1016/S2352-3018(20)30211-3
pmc: PMC7482434
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e629-e640Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Medical Research Council
ID : MC_PC_19012
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 World Health Organization; licensee Elsevier. This is an Open Access article published under the CC BY 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.
Références
AIDS Behav. 2020 Sep;24(9):2473-2476
pubmed: 32333204
AIDS. 2007 Nov;21 Suppl 6:S55-63
pubmed: 18032940
AIDS Behav. 2014 Oct;18 Suppl 5:S505-15
pubmed: 23842717
J Int AIDS Soc. 2017 Jul 21;20(Suppl 4):21647
pubmed: 28770599
Confl Health. 2018 Jul 2;12:30
pubmed: 29988565
J Infect Dis. 2019 Dec 18;:
pubmed: 31851759
Pathog Dis. 2018 Jul 1;76(5):
pubmed: 29986020
J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):365-76
pubmed: 25803164
J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):220-224
pubmed: 24047971
J Int AIDS Soc. 2019 Nov;22(11):e25414
pubmed: 31729195
J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):199-206
pubmed: 22027872
J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):45-51
pubmed: 24872139
AIDS. 2015 Sep 10;29(14):1883-7
pubmed: 26372393
N Engl J Med. 2020 Jul 16;383(3):e11
pubmed: 32302075
PLoS One. 2016 May 09;11(5):e0154893
pubmed: 27159260
EClinicalMedicine. 2020 Apr 22;22:100342
pubmed: 32322805
Lancet Glob Health. 2020 Sep;8(9):e1132-e1141
pubmed: 32673577
AIDS. 2005 Feb 18;19(3):345-8
pubmed: 15718848
Lancet HIV. 2020 May;7(5):e301
pubmed: 32339471